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EFFECT OF DIFFERENT TYPES OF STATINS: SIMVASTATIN, 
LOVASTATIN AND PITAVASTATIN ON GLUCOSE-STIMULATED INSULIN 
SECRETION AND INSULIN CONTENT FROM CLONAL PANCREATIC BETA-
CELLS (INS-1) 
GRACE MARSELINA DATU TASIK 
 
ABSTRACT 
 
Objective. Cardiovascular disease (CVD) remains the leading cause of death 
globally. Reducing high blood cholesterol, which is a dominant risk factor for CVD events, 
is an essential goal of medical treatment. Statins are known as first‐choice agents. 
However, clinical trials report that some statins increased the risk for type 2 diabetes (T2D). 
Our objective was to investigate the effect of different statins on insulin secretion and 
content from pancreatic β-cells after chronic and acute exposure and determine the 
underlying mechanisms. 
Methods. The effects of simvastatin, lovastatin and pitavastatin on GSIS and 
content were studied in clonal pancreatic β-cells (INS-1 832/13) cultured in high glucose 
(12 mM). Insulin content and secretion were measured after chronic and acute incubation 
of statins using homogenous time-resolved fluorescence (HTRF) insulin assay kit (Cisbio). 
Intracellular Ca2+ was measured using fura-2 AM (Invitrogen). 
Results. Simvastatin (25-200 nM) and lovastatin (50-200 nM) significantly 
inhibited GSIS and depleted insulin content in a dose-dependent manner after 72-hour 
viii 
 
exposure. When the secretion level was normalized for content, the inhibitory effect was 
not observed. Simvastatin (200 nM) also increased the amplitude of intracellular Ca2+ 
oscillations at low glucose, but this was not reflected in the amplitude of oscillatory insulin 
release. In contrast, pitavastatin (25-200 nM) did not affect GSIS and only decreased 
insulin content at the highest dose tested.  
Conclusion. Inhibition of GSIS by simvastatin and lovastatin could be due to 
depletion of insulin content. Decreased Ca2+ sensitivity may also contribute to inhibition 
of GSIS by simvastatin. Pitavastatin had less inhibitory effect on GSIS and insulin content 
as compared to simvastatin and lovastatin indicating that not all lipophilic statins have a 
detrimental impact on GSIS. We suggest that statins may have differential mechanistic 
effects on β-cells some of which may contribute to the risk of T2D. 
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INTRODUCTION 
 
 
Diabetes 
Diabetes mellitus is a fast-growing global health problem in both industrialized and 
developing countries. International Diabetes Federation (2015) estimated that in 2017 there 
are 451 million (age 18–99 years) people with diabetes worldwide and projected to increase 
to 693 million by 2045. In the United States, National Diabetes Statistic Report (2017) 
predicted that 30.3 million people of all ages or 9.4% of the national population had 
diabetes in 2015. The two major forms of diabetes are type 1 and type 2 diabetes. Both 
types are characterized by progressive β-cell failure. In type 1 diabetes (T1D), this is caused 
by an autoimmune assault against the β-cells, inducing progressive β-cell death. Type 2 
diabetes (T2D), which accounts for 90 to 95% of diabetes worldwide, develops as a 
combination of insulin resistance and progressive beta cell dysfunction (Cederberg et al., 
2015).  The pathogenesis of T2D is more variable, comprising different degrees of β-cell 
failure relative to varying degrees of insulin resistance (Cnop et al., 2005) and recent 
studies suggest that statins, widely used in the treatment of hypercholesterolemia, may 
contribute to the increased risk of T2D. As the incidence of cardiovascular disease is higher 
in diabetics when compared to non-diabetics, this finding has raised concern among 
clinicians and patient alike. 
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Atherosclerotic Cardiovascular Disease 
Cardiovascular disease (CVD) is a well-known predictor of metabolic syndrome 
and a major non-communicable disease worldwide. According to WHO (2012), CVD 
remains the leading global cause of death, accounting for 17.3 million deaths per year and 
it is predicted to grow to more than 23.6 million by 2030 (Laslett, 2012). In the United 
States, CVD is a significant public health problem affecting one in three American adults, 
accounting for nearly 31% of all deaths (Mozaffarian et al., 2015). Cardiovascular disease 
represents a number of heart and blood vessel diseases such as coronary heart disease, 
congestive heart failure, stroke and atrial fibrillation. 
The major cause for morbidity and mortality associated with CVD is 
atherosclerosis, an inflammatory disease in the arteries (Garg, 2015). Atherosclerotic 
cardiovascular disease (ASCVD) is a multifactorial condition involving dyslipidemia 
which associated with other metabolic alterations (Barquera, 2015). The term 
atherosclerosis is of Greek origin, meaning thickening of the intimal layer of arteries and 
accumulation of fat (Rafieian-Kopaei, 2014). Many modifiable risk factors for 
atherosclerosis have been identified by large prospective observational studies (Herrington, 
2016) and one of them is an elevated concentration of low-density lipoprotein (LDL) 
cholesterol which alters cellular permeability and progressively affect the arterial walls. 
This substrate promotes an inflammatory response in which circulating monocytes adhere 
to the endothelial cells which, in turn, express adhesion molecules and selectins, increasing 
monocytes migration to the sub-endothelial space. Monocytes are then converted to foamy 
macrophages rich in cholesterol esters and free fatty acids, which infiltrate the arterial walls 
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and cause a pathological intimal thickening lesion inducing the conversion of the lipid pool 
to a necrotic core. The atherosclerotic plaque containing foamy macrophages is prone to 
plaque fissure or rupture that may lead to a fatal thrombosis which may manifest as 
coronary heart disease, stroke, and peripheral arterial disease (Barquera, 2015). 
Statins 
Statins were discovered in 1976 by Akira Endo and approved for clinical use as 
potent LDL-Cholesterol lowering medication by the FDA in 1987. Statins act upon 
hepatocytes, reversibly and competitively block the action of HMG-CoA reductase, an 
enzyme that converts HMG-CoA into mevalonate, necessary for de novo cholesterol 
synthesis (Figure 1). 
Figure 1. Statin mechanism of action 
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Statins alter the conformation of HMG-CoA reductase when binding to its active 
site which prevents this enzyme from reaching a functional structure. The change in 
conformation at the active site makes these drugs very effective and specific. Binding of 
statins to HMG-CoA reductase is reversible, and their affinity for the enzyme is in the 
nanomolar range, as compared to the natural substrate, which has micromolar affinity 
(Corsini et al., 1999). 
The inhibition of HMG-CoA reductase regulates the reduction of intracellular 
cholesterol, activates protease which slices the sterol regulatory element binding proteins 
(SREBPs) from the endoplasmic reticulum. SREBPs are translocated at the level of the 
nucleus, where they upregulate LDL receptor gene expression (Figure 1). The reduction of 
cholesterol in hepatocytes leads to the increase of hepatic LDL receptors, that determines 
the reduction of circulating LDL and of its precursors, intermediate density lipoproteins 
(IDL) and very low density lipoproteins (VLDL) (Sehayek, 1994). As a result, studies have 
evaluated that statins reduce the progression and may promote the regression of ASCVD. 
Such effects were translated in significant decline in cardiovascular morbidity and 
mortality rates proved in many clinical trials (Vaughan et al., 2000). 
Statins are also known to have cholesterol-independent or “pleiotropic” beneficial 
effects because mevalonate, the product of HMG-CoA reductase reaction is not only the 
precursor of cholesterol synthesis but also for non-steroidal isoprenoidic compounds. The 
pleiotropic effects including improvement of endothelial function by the endothelial 
synthase (eNOS) up-regulation, decrease in vascular smooth muscle cell (VSMC) 
proliferation and macrophage proliferation, reduction of platelet activity, stabilization of 
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atherosclerotic plaques, antioxidant, anti-inflammatory and immunomodulatory effects 
(Stancu et al., 2001; Jasinska et al., 2007). 
Since 2010, different types of statins are available in the market included 
simvastatin, atorvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and fluvastatin. 
A systematic review by Stancu and colleagues reported that all statins reduce LDL 
cholesterol non-linearly dose dependent and after administration of single daily dose and 
efficacy of triglyceride reduction synchronizes LDL cholesterol reduction. 
This thesis will focus on three different major statins: simvastatin, lovastatin, and 
pitavastatin. There are a number of classification criteria for statins, including the 
derivation, liver metabolism, physico-chemical properties (as mentioned in Table 1) and 
specific activity. Simvastatin and lovastatin are derived from fungal fermentation, whereas 
pitavastatin is obtained synthetically. In terms of the activity form, pitavastatin is 
administered as an active compound (salt and acid forms, respectively). As opposed to 
simvastatin and lovastatin, which are administered as non-active compounds (lactone 
form). Both statins need to be enzymatically hydrolyzed to generate active forms (Stancu 
et al., 2001 and Blumenthal et al., 2000). 
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Type of 
Statins 
Trade 
Name 
Physico-
chemical 
Property 
Potency (in 
order of 
decreasing 
potency) 
Beneficial impact on Clinical 
Practice 
Simvastatin Zocor, 
FloLipid 
Lipophilic High Potency - Potent Inhibitor of HMG CoA 
Reductase 
- Reduce TC and LDL-C and increase 
HDL-C after 5.4 years of follow up () 
Lovastatin Mevacor, 
Altoprev 
Lipophilic Medium 
Potency 
- Inhibitor of HMG CoA Reductase 
- Reduce LDL-C, TG, VLDL and 
ApoB and slightly increase HDL-C () 
Pitavastatin Livalo, 
Livazo 
Lipophilic Has not yet 
been fully 
established 
- Inhibitor of HMG CoA Reductase 
- Significant reduction of TC, TG & 
LDL-C concentration at week 12 
(Saito et al) 
Table 1. Characteristics of statins 
In terms of physico-chemical property, there are two type of statins, lipophilic and 
hydrophilic statins. Both categories have an inhibitory effect on HMG-CoA reductase, but 
through distinct mechanisms. Pravastatin, a hydrophilic statin, requires carrier-mediated 
uptake, while lipophilic statins such as simvastatin, lovastatin and pitavastatin passively 
diffuse through the hepatocellular membrane. However, in this thesis, our study will focus 
on lipophilic statins (simvastatin, lovastatin and pitavastatin). As a result, these lipophilic 
agents are also able to diffuse in extrahepatic tissues, thus decreasing their hepatoselectivity 
(Schachter et al., 2005 and Shitara 2006). The influence of extrahepatic tissues led Brault 
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and colleagues suggested that lipophilic statins may have higher adverse effects on insulin 
sensitivity and supported by Baker et al., (2010). They found out that simvastatin, and other 
lipophilic statins, atorvastatin and rosuvastatin exacerbate insulin sensitivity, whereas 
pravastatin (hydrophilic statin) has significant improvement. Another study by Yada et al., 
(1999) reported that inhibition of insulin secretion in vitro parallels statin lipophilicity. 
However, these investigations did not include pitavastatin, another lipophilic statin which 
has a positive effect towards GSIS in our study.  
Dilemma of Statins Treatment 
Reducing high blood cholesterol, especially LDL cholesterol which is a dominant 
risk factor for ASCVD events is an important goal of medical treatment. 
Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, known as statins are the 
first‐choice agents. As the potent inhibitors of HMG-CoA reductase, a hepatic enzyme that 
functions in the rate-determining step of cholesterol metabolism, statins initiate cellular 
reactions in cholesterol homeostasis that ultimately upregulate low-density lipoprotein 
(LDL) cholesterol receptor production. Circulating LDL cholesterol particles in the 
bloodstream bind to these LDL receptors and are then removed from the bloodstream and 
degraded intracellularly, resulting in lower plasma levels of cholesterol (Agarwala, 2018). 
Decades of research have demonstrated that statins improved clinical outcomes and 
reduced the progression of ASCVD (Taylor et al., 2017). Their important role in primary 
and secondary prevention of ASCVD morbidity and mortality is well established. 
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 However, during the past decade, as the prescription rates have increased, concern 
has been raised about the use of statins and the development of diabetes (Carrao et 
al.,2014). Trials and meta-analyses have reported contradictory results regarding new-
onset diabetes with statins. In 2009, the diabetogenic impact of statin was first discovered 
in the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention 
Trial Evaluating Rosuvastatin) trial, a double-blind randomized study of 17,802 subjects 
assigned to rosuvastatin 20 mg or placebo. 
A meta-analysis of 13 statin trials with 91,140 non-diabetic participants, have 
suggested that statins increase the risk of type 2 diabetes (T2D) (Sattar et al., 2010). As the 
incidence of cardiovascular disease is greater in diabetics as compared to non-diabetics this 
finding has raised concern among clinicians and patients alike (Agarwala, 2014). In 
February 2012, Food and Drug Administration released changes to statin safety label to 
include that statins have been found to increase haemoglobin (HbA1C) and fasting serum 
glucose levels (Chogtu, 2015). Another supporting data from several population-based 
studies have indicated a 10–22% increased risk of diabetes with statins (Cederberg et al., 
2015). 
Possible Mechanisms behind the Association of Statin and Increased Risk of Diabetes 
Mechanistic studies involving statin treatment in new onset diabetes has been 
observed in a population based-study and multiple clinical trials. A population-based study 
conducted by Cederberg et al., (2015) has discovered that statin treatment is associated 
9  
with 24% decreased insulin sensitivity and 12% reduction in insulin secretion after 6 years 
of follow up. 
Moreover, Brault et al., (2014) in a recent systematic review have highlighted three 
primary mechanisms behind the onset of statin-induced diabetes. First, certain statins affect 
insulin secretion through direct, indirect or combined effects on calcium channels in 
pancreatic β-cells.  Second, statin therapy decreases important downstream products from 
mevalonate pathway, such as Coenzyme Q10, farnesyl pyrophosphate, geranylgeranyl 
pyrophosphate, and dolichol; their depletion leads to reduced intracellular signaling. Third, 
statins impede translocation of glucose transporter 4 (GLUT 4) in response to statin 
exposure results in hyperglycemia and hyperinsulinemia. Other potential mechanisms 
impacted the association of statins and new-onset diabetes are: statin interference with 
intracellular insulin signal transduction pathways via inhibition of necessary 
phosphorylation events and reduction of small GTPase action; inhibition of adipocyte 
differentiation leading to decreased peroxisome proliferator activated receptor gamma and 
CCAAT/enhancer-binding protein which are important pathways for glucose homeostasis; 
decreased leptin causing inhibition of β-cells proliferation and insulin secretion; and 
diminished adiponectin levels.  
Furthermore, Urbano and colleagues (2017) discovered that inhibition of insulin 
release from β-cells is linked with mitochondrial dysfunction due to oxidative stress 
conditions. The side effect of effective blocking of cholesterol synthesis by statins through 
the mevalonate pathway downregulates the production of CoQ10, a major cellular defense 
system to oxidative stress. 
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-cell function 
The ability of pancreatic β-cell to synthesize, package and release insulin upon 
demand is crucial to control blood glucose homeostasis within a narrow physiological 
range of 4.4 to 6.1 mmol/L (79.2 to 110 mg/dl) as measured by fasting blood glucose. 
Dysfunction in normal secretion of insulin by pancreatic -cells or impaired insulin action 
as in insulin resistance can lead to hyperglycemia and the onset of T2D (Deeney, et al., 
2000; Barbara E. Corkey 2012; ADA  2015). Diagnostic criteria for T2D is based on ≥126 
mg/dL (7 mmol/L) fasting glucose in the blood, which could be caused, by not only a lack 
of insulin but also the inability of insulin to efficiently lower glucose in the blood and 2-
hour oral glucose tolerance test (OGTT; ≤ 200 mg/dL) (Lovre et al., 2015)) 
Insulin secretion in β-cells  
Insulin, a critical regulator of glucose homeostasis, is synthesized as preproinsulin 
and processed to proinsulin. Proinsulin is then converted to insulin and C-peptide and 
stored in secretary granules awaiting release from β-cells on demand. The β-cells respond 
to many nutrients in the blood circulation and glucose is known to be the primary stimuli 
for insulin release by generating triggering and amplifying signals in cells (Fu et al., 2013; 
Henquin et al., 2000 and Kalwat et al., 2017). The triggering and amplifying pathways 
have been associated with first- and second-phase insulin secretion, respectively. 
First phase of insulin release is defined as a rapid and robust spike of insulin 
secretion.  It starts when the glucose enters the β cell-through GLUT1 (GLUT2 in rodents) 
and undergoes rapid metabolism through glycolytic and mitochondrial fuel oxidative 
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pathways to produce ATP and thereby increase the ratio of ATP to ADP concentration 
within the first minute of stimulation (Kalwat et al., 2017 and Civelek et al., 1996). 
Elevation of this ratio results in the closure of ATP-sensitive potassium (KATP) channels 
thereby triggers membrane depolarization and opening of voltage-gated Ca2+ channels 
which leads to intracellular Ca2+ influx into the cell. It stimulates fusion of insulin granules 
to the plasma membrane (insulin exocytosis). The ability of glucose to elicit an increase in 
cytosolic [Ca2 +] causing insulin exocytosis is referred to as the triggering pathway (Figure 
2). After the first-phase peak, the insulin release rate drops, but is sustained in the ‘second-
phase’ which persists until euglycemia (normal blood glucose) is restored (Rorsman & 
Renstrom, 2003). 
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Figure 2: Overview of glucose-stimulated triggering pathway of insulin secretion in 
the β cell. Glucose enters the β cell through the GLUT1 glucose transporter (GLUT2 in rodents) 
and undergoes rapid metabolism through glycolytic and mitochondrial fuel oxidative process to 
generate ATP and thereby increase the ratio of ATP to ADP which lead to closure of the KATP 
channel. This closure causes membrane depolarization then activates voltage-dependent calcium 
channels (VDCC) ) to allow the inﬂux of calcium that constitutes the triggering pathway required 
for insulin secretion 
 
In addition, studies conducted by Deeney and colleagues (2001) demonstrated that 
glucose-stimulated insulin secretion from pancreatic -cells is oscillatory due to glucose 
metabolism regulated by phosphofructokinase (PFK). They reported that one of the major 
metabolic stimulus-secretion coupling factors is the ATP/ADP ratio. As an important part 
of the triggering pathway (figure 2), oscillations in ATP/ADP ratio causes activation and 
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deactivation (opening and closure) of KATP channels, leading to another oscillation in both 
membrane potential and cytoplasmic free Ca2+ which thereby triggers insulin exocytosis. 
These oscillations become substantial given that they act as a regulator of insulin secretion 
by preventing chronic elevation of Ca2+, thus results in an efficient reduction of blood 
glucose. In type 2 diabetes, the oscillatory system is often dampened or changed. 
Figure 3. Overview of glucose-stimulated amplifying pathway of insulin secretion in 
the β cell. In addition to triggering pathway, there are other metabolites such as LC-CoA that are 
responsible for further exocytosis of insulin granules. LC-CoA directly or indirectly through the 
PKC pathway is responsible for exocytosis of insulin granules shown above. 
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The amplifying pathway depends on the initial triggering signal in order to induce 
insulin secretion. In the amplification pathway (Figure 3), glucose-induced insulin 
secretion is further elevated above and beyond the effect of the increased intracellular Ca2+ 
level. 
Relationship between Cholesterol, β-cell function and Glucose-stimulated Insulin 
Secretion 
Biosynthesis of cholesterol plays a crucial role in eukaryotic cell growth, providing 
building blocks for cell membranogenesis, and for the synthesis of sterol and non-sterol 
products which are crucial for normal cell function. Cholesterol can be obtained from 
dietary or exogenous sources and synthesized from acetate precursors (Russell, 1992). 
Humans are able to synthesize approximately 700-900 mg of cholesterol per day, while 
300-500 mg are absorbed daily from dietary intake. Normal daily cholesterol turnover is 
accounted for by excretion in the gastrointestinal tract (600 mg/day), conversion to bile 
acids (400 mg/day), sloughing skin (85 mg/day), biosynthesis of steroid hormones (50 
mg/day), and by incorporation into membranes of actively dividing cells (Dietschy, 1984). 
Diabetes-related research studies have revealed that membrane cholesterol levels 
in adipocytes, skeletal muscle fibers and pancreatic  cells influence insulin action and 
insulin secretion. Consequently, it is assumed that dysregulated cell cholesterol 
homeostasis could be highly associated with type 2 diabetes (T2D). These studies have 
mentioned that cholesterol itself and its biosynthesis intermediates may influence insulin 
secretion particularly through functions of membrane microdomains (Grice & Jeffrey 
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(2017); Hao & Bogan, 2009). Some findings suggested that abundance cholesterol 
blunts -cell function and GSIS. For instance, Kruit et al., (2011) explain that β-cells with 
reduced ABCA1 cholesterol transporter show excess cholesterol contents associated with 
inhibition in GSIS. Additionally, Xia et al., (2004) find that lowered cholesterol by methyl-
β-cyclodextrin (MβCD) in the HIT-15 β-cell-line increased insulin secretion. 
Furthermore, Bogan & Hao, (2009) cholesterol-overloaded β-cells are 
unresponsive to glucose stimulation in terms of membrane depolarization, PIP2 hydrolysis, 
and actin reorganization which lead to lowered insulin secretion. In the presence of 
cholesterol accumulation, abundance PIP2 will decrease ATP sensitivity by activating the 
KATP channel and blunt β-cell membrane depolarization in response to glucose. This model 
is consistent with the finding that increased PIP2 causes a reduction in GSIS by rendering 
KATP channels insensitive to ATP. 
However, a few studies show the opposite results. Reduction of cholesterol by 
MβCD was also done by Vikman et al., (2009) and their finding was depletion of 
cholesterol reduced insulin secretion in mouse islets. Insulin secretion reduction in mouse 
pancreatic islets was also observed after inhibition of farnesyl synthesis, cholesterol 
intermediates (Xia et al., 2008).  Supporting this report, Linetti et al., (2010) and Parpal et 
al., 2001, mentioned that cholesterol is involves in exocytosis and signal transduction. 
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Aim 
This study aimed to identify the effect of different types of statins: simvastatin, 
lovastatin and pitavastatin on insulin secretion and insulin content from pancreatic β-cells 
after chronic and acute exposure. We hypothesized that as a consequence of cholesterol 
biosynthesis which results in stimulation of PIP2 hydrolization induction of influx of  Ca
2+ 
and GSIS stimulation through IP3 and DAG production, statin treatment at short duration 
may trigger hypersecretion of insulin via glucose stimulation and this recurrent 
hypersecretion could lead to an imbalance between insulin biosynthesis and release. 
Consequently, a reduction in insulin content and thereby a decline in GSIS could occur. 
The specific objective of this study was to investigate 1) whether all lipophilic 
statins (simvastatin, lovastatin, pitavastatin) have harmful effects towards secretory insulin 
and its content and 2) the mechanism behind the impairment in GSIS mediated by statins 
through the oscillatory behavior of intracellular Ca2+ and kinetic insulin secretion. 
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METHODS AND MATERIALS 
 
INS-1 Cell Culture 
All experiments in this study used Clonal pancreatic β-cells INS-1 832/13 
(Hohmeier et al., 2000). This cells were grown in 11 mM glucose in Roswell Park 
Memorial Institute (RPMI 1640) media containing 10 mM 4-(2-HydroxyEthyl)-1-
Piperazine Ethane Sulfonic acid (HEPES), 1 mM pyruvic acid, 50 µM β-mercaptoethanol 
(BME), 2 mM glutamine, 10 % Fetal Bovine Serum (FBS), 50 IU/ml penicillin and 50 
µg/ml streptomycin. Cells were split once a week to carry the cell line and to grow cells in 
multi-well plates for experiments. 
Cells were plated in four different plates: 12, 24, 48 and 96 well plates (Corning, 
NY) to reach the cell densities on the day secretion was performed; approximately 960,000-
1,000,000 cells/well for a 12-well plate; 480,000-500,000 cells/well for a 24-well plate; 
240,000-250,000 cells/well for a 48-well plate and 120,000 cells/well for a 96-well plate. 
The cell number seeded in these wells was based on the doubling time which was 32 hours 
in 11 mM glucose media. 
Cells were usually grown one or two days prior to chronic exposure with different 
type of statins: pitavastatin, lovastatin, and simvastatin for three days. Afterwards, cells 
were ready for the glucose-induced insulin secretion (GSIS) experiment (Figure 4). Shorter 
statin incubations were also performed as part of a time course, which include 7, 14, 24 
and 48 hrs of statins exposure.  
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Figure 4. Experimental timeline of INS-1 treated with statins chronically 
 
Insulin secretion  
The INS-1 cells were ready for glucose-induced insulin secretion (GSIS) 
experiment after chronic exposure with 4 different statins: pitavastatin, pravastatin, 
simvastatin and lovastatin for 3 days. There are 4 steps required in this GSIS experiment. 
First, these cells were incubated for 2 hours in 2 mM glucose (2 G) RPMI, containing 10 
mM HEPES, 2 mM glutamine and 1 mM pyruvic acid. Second, after 2 hours of incubation 
in 2G RPMI, cells were pre-incubated for 30 minutes with 2G Krebs-Ringer Bicarbonate 
Buffer (KREBS) containing 119 mM NaCl, 4.6 mM KCL, 5 mM NaHCO3, 2 mM CaCl2,1 
mM MgSO4, 0.15 mM NaHPO4, 0.4 mM KH2PO4, 20 mM HEPES and 0.05% Bovine 
Serum Albumin (BSA) (Sigma, St. Louis, MO) at pH 7.4, in a water bath at 37°C. After 
30 minutes of pre-incubation, cells were placed on ice for 5 minutes to lower the 
temperature. 
Third, the 1mM G KREBS was dumped from wells with attached cells and the test 
solutions of 1G, 3G, and 12G KREBS were added to the cells immediately where the plates 
were still on the ice. These cells were then incubated for additional 2 hours in a 37°C water 
bath. After the 2 hrs incubation, plates were placed on top of the ice for 5 minutes to 
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stabilize the temperature. Lastly, samples of secreted insulin in the media were diluted at 
1:1 in 1% BSA KREBS. Diluted samples were centrifuged for 3 minutes at 4000 RPM at 
4°C to separate any cells and residue transferred throughout the sampling and dilution 
process. Released insulin and content were stored at -20°C for a later assay process. 
When necessary, samples were appropriately diluted before being assayed. This 
dilution factor was based on a test assay performed after the experiment. The insulin 
secretion assay was performed with a FRET-based HTFR assay kit from Cisbio, and 
fluorescence was measured using the Tecan Infinite M 1000 PRO spectrophotometer 
(fluorescence intensity at; excitation/emission 317/620 nm with bandwidth 20/10nm, gain 
180, flashes on mode2 [100HZ]:50 and z-position of 24000 µm). Two antibodies that were 
used in this assay must be bound to insulin for the FRET signal to be measured. 
 
Figure 5. Steps of Glucose-Stimulated Insulin Secretion 
 
The results of the assay were calculated via Microsoft Excel based on the equation 
from the insulin standard curve, dilution factor, volume of the test solution used and cell 
number per well. In each experiment and for every condition, insulin secretion was 
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measured from duplicate (for 24 well-plate), triplicate (for 48 well-plate) or quadruplicate 
(for 96 well-plate) wells. 
 
Insulin Content Measurement 
One well from each condition of the 12- and 24-well plate, two wells from each 
condition of the 48-well plate and four wells from each condition of the 96-well plate were 
used to extract the cells for insulin content. After the old media containing 11 mM of 
glucose was removed from the plate, 0.05 % trypsin was added to the desired wells at such 
volume: 1 ml/well for 12-well plate, 500 µl/well for 24- and 48-well plate, and 150 µl/well 
for 96-well plate. The plates were then placed inside the incubator for approximately 5-8 
minutes until the cells rounded up (trypsinized).  
Then, the trypsinized cells from the desired wells from each condition were 
collected into a 1.5 ml Eppendorf tube and placed on ice to deactivate the activity of the 
trypsin. After the collection of INS-1 cells into the Eppendorf tube, 11 µl of the 
experimental and control condition sample was transferred onto the hemocytometer to 
measure the cell number. The obtained cell count was calculated and adjusted for per ml 
and per well. 
The rest of the collected cells inside the Eppendorf tube were centrifuged at 4000 
rpm for 3 minutes to collect the pellet and then lysed in 150 µl PBS solution containing 
0.1% Triton X-100 (Sigma, St. Louis, MO) and 25 mM NaOH. This lysing process was to 
extract the insulin content from the INS-1 cells which was not secreted. Afterwards, 150 
21  
µl KREBS-containing 1% BSA was added to the Eppendorf containing cells and insulin 
content. Content samples were stored at -20°C and assayed as described for secreted insulin 
samples. 
Statin Preparation 
Pitavastatin 
Pitavastatin is prepared from a Ca2+ salt that binds two statin molecules per complex 
and is dissolved in DMSO to 10 mM (Figure 6). This statin is then further diluted in DMSO 
to reach the 200 µM concentration and aliquoted in several Eppendorf tubes to be readily 
used. The stock of pitavastatin at 10 mM and at 200 µM were stored in -20oC. 
 
Figure 6. Chemical Structure of Pitavastatin 
 
22  
Simvastatin & Lovastatin 
Both simvastatin and lovastatin structure contains lactone (Figure 7). Before 
diluting in DMSO, these two types of statin should be converted to their active forms by 
dissolving 4 mg of simvastatin and lovastatin respectively in 100 μl of ethanol. Afterwards, 
150 μl of 0.1 N NaOH is added to the solution (simvastatin and lovastatin), and 
subsequently incubated at 50 °C for 2 hours. The pH is then brought to 7.0 by HCl. 
After the activation, simvastatin and lovastatin are dissolved in ethanol to 20 mM 
and further diluted in DMSO until it reached the desired concentration of 200 µM and then 
aliquoted. The stock and readily used aliquots of simvastatin and lovastatin were stored in 
4oC. 
 
Figure 7. Chemical Structure of Simvastatin and Lovastatin 
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Calcium Activity Measurement 
Intracellular calcium was measured using fura-2 AM (Invitrogen, Carlsbad, CA). 
Simvastatin- and pitavastatin-exposed INS-1 cells cultured in 35-mm glass bottom dishes 
(MatTek, Ashland, MA) were loaded with fura-2 (2 AM) with 0.1% pluronic acid (Thermo 
Fisher Scientific) for 30 min, The solution was then changed to KREBS for another 30 
min, Imaging was performed on an Olympus DSU spinning disk confocal microscope at 
20X magnification at 37 °C. Fluorescence images were captured every 15 seconds with 
wavelengths of 340/380 nm dual excitation and 510 nm emission. Data were analyzed 
using Nikon Cell Sense software. Imaging experiments were performed in the DOM 
Imaging Cores at BUSM under the direction of Dr. Michael Kirber. 
 
Measurement of Kinetic Insulin Secretion in INS-1 Cells  
INS-1 cells (control) and simvastatin-treated INS-1 cells were perifused in a 
column as explained by Cunningham, Deeney, Bliss, Corkey, & Tornheim (1996). Two 
sets of tube containing INS-1 cells with and without simvastatin exposure was laid between 
2 layers of Cytodex microcarrier beads (Sigma). The column used was 0.4 cm in diameter 
and 4 cm high and contained in a temperature controlled environment at 37 °C. Perifusion 
reagents were pumped through the column at 0.3 ml/minute using an analog tubing pump 
(Ismatech REGLO pump, type ISM 827, model 78,016–30; Cole-Parmer Instrument Co., 
Chicago, IL). 
Both INS-1 cells (control) and simvastatin-treated INS-1 cells were perifused with 
KREBS-Ringer Bicarbonate buffer with added 0.5 % BSA for 30 minutes to reach the 
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equilibrium state. After 30-minutes incubation in KREBS, samples were collected at 15 
second intervals for 70 minutes. Basal insulin level was stimulated with 1 mM glucose 
perifusion for 20 minutes, perifusion was changed with higher glucose concentration at 3 
mM for 20 minutes. Then, maximum glucose level at 12 mM was perifused for 20 minutes. 
KREBS solution containing119 NaCl, 4.6 KCl, 5 NaHCO3, 2 CaCl2, 1 MgSO4, 0.15 
Na2HPO4, 0.4 KH2PO4, 20 HEPES, 0.05% BSA, pH 7.4. 
 
Statistical Analysis 
To statistically test the equality of means, this study used One Way Analysis of 
Covariance (ANOVA). Then, based on the equality or inequality of variances, statistical 
significance in each experiment was calculated using t-test: two sample assuming unequal 
or equal variances. The data are presented as the mean of three to six experiments with 
three to four replicates ± Standard Error of the Mean (S.E.M.) A p-value of <0.05 denoted 
as (*) was determined to be statistically significant. 
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RESULTS 
 
Glucose-Stimulated Insulin Secretion (GSIS) from INS-1 Cells Cultured in High 
Glucose (11 mM) 
INS-1 cells were cultured in 11 mM glucose for four or five days before performing 
the GSIS experiment. The purpose was to mimick the hyperglycemic condition in 
overweight and obese diabetic individuals. 
The INS-1 cells then were acutely stimulated for two hours at elevated glucose 
concentrations: 1, 2, 4, 6, and 8 mM which resulted in a sigmoidal curve of insulin secretion 
(Figure 8). There was not much change in insulin secretion when glucose concentration 
was raised from 1 mM to 2 mM compared to insulin secretion from 4 mM to 8 mM glucose, 
which resulted in 5-fold increase. However, the largest change (71%) was observed when 
glucose was altered from 4 mM to 6 mM. 
As shown in Figure 8, the level of insulin release at basal (1 mM) and stimulated 
(8 mM) conditions are 9 ng/106 cells and 95 ng/106 cells, respectively. These numbers were 
not exactly the same over several experiments, however it followed a similar trend in which 
the switch of glucose concentration from 4 mM to 6 mM and 8 mM were highly significant.  
Basal insulin secretion at 1 mM and 2 mM glucose in this study ranged from 8-11 
ng/106 cells and 11-13 ng/106 cells, respectively. Meanwhile, insulin release at 8 mM was 
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relatively constant in the range of 94-95 ng/106 cells in all experiments. Overall, GSIS from 
1 mM to 8 mM glucose resulted in 8- to 11- fold stimulation of insulin release. 
 
Figure 8. GSIS from INS-1 cells cultured at high glucose. INS-1 cells were cultured in 11 
mM glucose for 4 or 5 days and induced during 2-hour incubation at increasing glucose 
concentrations, 1 mM, 2 mM, 4 mM, 6 mM and 8 mM. Insulin secretion increased -fold from mM 
to mM glucose. No apparent change was observed between 1 mM to 2 mM glucose (basal 
secretion). Similar results were observed in three other experiments and the graph above shows two 
independent experiments performed in 48-well plate with three to four replicates calculated as a 
mean ± S.E.M. *p<0.05, basal secretion at 1 mM glucose vs 2 mM, 4 mM, 6 mM & 8 mM (one-
way ANOVA followed by T-test). 
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Dose-Dependent Effects of Simvastatin on Insulin Secretion and insulin Content 
 INS-1 cells were cultured in 96-well plates with 11 mM glucose media. After one 
or two days of growth, simvastatin at increasing concentrations (25 nM, 50 nM, 100 nM 
and 200 nM) was added to the cells and incubated for three days (68-74 hours). On the day 
of the experiment, GSIS at 12 mM glucose was measured from control and simvastatin 
treated cells. Control cells were also incubated with 1 mM glucose to monitor the fold 
increase in insulin secretion over multiple experiments. 
 Basal insulin secretion at 1 mM glucose of INS-1 cells chronically cultured in high 
glucose was 8.5 ng/106 cells. When glucose was acutely switched to 12 mM, insulin 
secretion increased 4 fold (Figure 9A). These results are important to indicate that the cells 
were responsive to glucose before measuring the insulin secretion from simvastatin-
exposed INS-1 cells. 
 Figure 11B shows that in the presence of the lowest dose of simvastatin (25 nM), 
GSIS from INS-1 was significantly reduced by 17%. This significant reduction of insulin 
was also observed in INS-1 cells exposed to 50 nM and 100 nM simvastatin with relatively 
similar percentage, 25% and 28%, respectively. The greatest inhibition of GSIS by 41% 
when compared to control was measured in cells treated with 200 nM simvastatin. These 
results confirm that simvastatin dose-dependently inhibits GSIS. In order to determine 
whether this dose-dependent restriction was due to an impact on the insulin reservoir or 
exocytosis we measured the insulin content of those cells. 
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Figure 9. Basal and stimulated insulin secretion (A) and simvastatin dose-dependently 
inhibited GSIS from INS-1 Cells (B). INS-1 cells were cultured in 11 mM glucose for 4 to 5 
days. After one or two days growing in high glucose, simvastatin at four different concentrations, 
were added to these cells for three days. Then, they were acutely stimulated to 12 mM and insulin 
secretion as well as content were measured. The graph above shows six experiments performed in 
96-well plate with three to four replicates calculated as a mean ± S.E.M. Similar results were 
observed in three experiments using 48-well plate & one independent experiment from 24-well 
plate. *p<0.05, control vs 25 nM, 50 nM, 100 nM & 200 nM simvastatin (one-way ANOVA 
followed by T-test). 
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 Control INS-1 cells extracted from 96-well plates had 1108 ng/106 cells of insulin 
content on average (Figure 10A). 25 nM simvastatin did not significantly decrease the 
insulin content even though the content tended to be lower.  Higher concentrations of 
simvastatin (50 nM, 100 nM and 200 nM) significantly reduced the content by 41%, 33% 
and 47%, respectively. 
 Insulin secretion from simvastatin-treated INS-1 cells (Figure 9B) was plotted as 
percent content (Figure 10B). When normalized for content, the insulin secretion was 
relatively unchanged indicating that the inhibition of insulin secretion mediated by 
simvastatin was likely to be due to the reduction in content.  
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Figure 10. Simvastatin reduced insulin content after chronic incubation (A), and 
insulin secretion from figure 9B measured in units of "percent content" (B. Fig. 10A 
shows four experiments performed in 96-well plates calculated as a mean ± S.E.M. *p<0.05, control 
vs 25 nM, 50 nM, 100 nM & 200 nM simvastatin (one-way ANOVA followed by T-test).  Decrease 
in insulin content in such dose-dependent manner was also shown in three experiments using 48-
well plate & one independent experiment from 24-well plate. 
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Dose-Dependent Effects of Lovastatin on Insulin Secretion and insulin Content 
 INS-1 cells were cultured in 96-well plates with 11 mM glucose media. After one 
or two days of growth, lovastatin at increasing concentrations (25 nM, 50 nM, 100 nM and 
200 nM) was added to the cells and incubated for three days (68-74 hours). On the day of 
the experiment, GSIS at 12 mM glucose was measured from control and lovastatin treated 
cells. Control cells were also incubated with 1 mM glucose to monitor the fold increase in 
insulin secretion over multiple experiments. 
 Basal insulin secretion at 1 mM glucose of INS-1 cells chronically cultured in high 
glucose was 7.7 ng/106 cells. When glucose was acutely switched to 12 mM, insulin 
secretion significantly increased by 4-fold to 34.75 ng/106 cells indicating that these cells 
were responsive to glucose and ideal for examining the effect of lovastatin (Figure 11A). 
 Incubation of lovastatin at the lowest dose (25 nM) did not inhibit insulin release. 
GSIS was significantly inhibited when the dose of lovastatin was raised to 50 nM, 100 nM 
and 200 nM. Secretion was reduced from 34.8 ng/106 cells (control group) to the range of 
26.6 ng/106 to 24.3 ng/106 cells for 50-200 nM lovastatin. This represented approximately 
26% decrease (Figure 11B). To further investigate the mechanism behind this restriction 
of GSIS by lovastatin, we then assayed, analyzed and calculated the insulin content from 
lovastatin-exposed cells. 
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Figure 11. Basal and stimulated insulin secretion (A) and lovastatin dose-dependently 
inhibited GSIS from INS-1 Cells (B). INS-1 cells were cultured in 11 mM glucose for 4 to 5 
days. After one or two days growing in high glucose, lovastatin at 25 nM, 50 nM, 100 nM & 200 
nM were added to cells for three days. The graph above shows four to five experiments performed 
in 96-well plates with three to four replicates calculated as a mean ± S.E.M. Similar results was 
observed in three experiments using 48-well plate & one independent experiment from 24-well 
plate. *p<0.05, control vs 25 nM, 50 nM, 100 nM & 200 nM lovastatin (one-way ANOVA followed 
by T-test). 
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 The insulin content from control cells for the lovastatin experiment was 1083 
ng/106 on average. Aligned with the effect of lovastatin on GSIS, insulin content at 25 nM 
lovastatin was 919 ng/106 cells and not significantly lower than the control. This is in 
contrast to higher concentrations of lovastatin (50 nM, 100 nM and 200 nM), which 
significantly reduced the content by 43%, 64% and 56%, respectively (Figure 12A).
 To determine whether the drop of insulin level was also because of the diminishing 
insulin content as seen with simvastatin, insulin secretion from lovastatin-treated INS-1 
cells (Figure 11B) was plotted as percent content (Figure 12B). This insulin secretion in 
the unit of percent content demonstrated a continual increase, implying that the inhibition 
of insulin secretion mediated by lovastatin was due to diminishing content. A greater 
inhibition in content in the case of lovastatin lead to a persistent increase in insulin secretion 
(Figure 12B). This results may also explain that the mechanism of insulin exocytosis may 
not be affected. 
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Figure 12. Lovastatin reduced insulin content after chronic incubation (A), and  
insulin secretion from figure 11B measured in units of "percent content" (B). Fig. 14A 
shows four experiments performed in 96-well plates calculated as a mean ± S.E.M. *p<0.05, control 
vs 25 nM, 50 nM, 100 nM & 200 nM lovastatin (one-way ANOVA followed by T-test). Decrease 
in insulin content in such dose-dependent manner was also shown in three experiments using 48-
well plate & one independent experiment from 24-well plate. 
35  
Dose-Dependent Effects of Pitavastatin on Insulin Secretion and insulin Content 
 INS-1 cells were cultured in 96-well plates with 11 mM glucose media. After one 
or two days of growth, pitavastatin at increasing concentrations (25 nM, 50 nM, 100 nM 
and 200 nM) was added to the cells and incubated for three days (68-74 hours). On the day 
of the experiment, GSIS at 12 mM glucose was measured from control and pitavastatin 
treated cells. Control cells were also incubated with 1 mM glucose to monitor the fold 
increase in insulin secretion over multiple experiments. 
 Basal insulin secretion at 1 mM glucose of INS-1 cells chronically cultured in high 
glucose was 10.58 ng/106 cells. When glucose was acutely switched to 12 mM, insulin 
secretion increased dramatically by almost 4-fold (Figure 13A) indicating that these cells 
were responsive to glucose and ideal for examining the effect of pitavastatin. 
 In contrast to simvastatin and lovastatin, pitavastatin from the lowest dose (25 nM) 
to highest dose (200 nM) did not significantly reduce insulin secretion after maximum 
glucose stimulation at 12 mM. A modest and fluctuated reduction in insulin content by 
10.8%, 4.2%, 8.4% and 18% was calculated after chronic exposure with pitavastatin at 25 
nM, 50 nM, 100 nM and 200 nM, respectively (Figure 13B).   
 In order to confirm this, we conducted GSIS experiments with identical conditions 
in 24-well plates to see if larger wells with four times more cells would behave in the same 
way. The insulin secretion from INS-1 cells cultured in 24-well plate was also unchanged 
when compared to control group after 3-days incubation of pitavastatin at increasing doses.
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Figure 13. Basal and stimulated insulin secretion (A) and pitavastatin did not 
significantly inhibited GSIS from INS-1 Cells (B). INS-1 cells were cultured in 11 mM 
glucose for 4 to 5 days. After one or two days growing in high glucose, pitavastatin at 25 nM, 50 
nM, 100 nM & 200 nM.were added to these cells for three days. Then, they were acutely stimulated 
to 12 mM and insulin secretion as well as content were measured. The graph above shows three 
experiments performed in 96-well plates with three to four replicates calculated as a mean ± S.E.M. 
Similar results was observed in one independent experiment using 24-well plate. *p<0.05, 1 mM 
vs 12 Mm; control vs 25 nM, 50 nM, 100 nM & 200 nM pitavastatin (one-way ANOVA followed 
by T-test). 
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 In terms of insulin content, INS-1 cells from control wells had 917 ng/106 cells on 
average. The content from 25-nM-pitavastatin-treated cells was even higher at 1045 ng/106 
cells and no change at all observed in content with 50 nM pitavastatin exposure when 
compared to control group (Figure 14A). Content started to decrease with 100 nM 
pitavastatin (21% decrease) and this reduction became significant (41% decrease) after 
pitavastatin dose was doubled to 200 nM, which left the cells with 532 ng/106 cells of 
insulin content.  
 Insulin secretion from pitavastatin-treated INS-1 cells (Figure 13B) was plotted as 
percent content (Figure 14B). After insulin secretion was corrected for content, a decrease 
in percent content at 25 nM pitavastatin and linear increase from 50 nM to 200 nM 
pitavastatin was shown. Interesting this increase is the result of pitavastatin to decrease 
insulin content while not similarly inhibiting insulin secretion.  
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Figure 14. Insulin content slowly lowered by high dose of Pitavastatin  (A), and insulin 
secretion from figure 15B measured in units of "percent content" (B). High dose 
pitavastatin (200 nM) significantly reduced insulin content in INS-1 cells for 3 days. Fig. 16A 
shows four experiments performed in 96-well plates calculated as a mean ± S.E.M. *p<0.05, control 
vs 25 nM, 50 nM, 100 nM & 200 nM pitavastatin (one-way ANOVA followed by T-test). No 
significant reduction in insulin content with lower dose (25 nM & 50 nM) was also found in two 
other experiments using 24- & 48-well plates. 
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Chronic INS-1 Cell Exposure to Simvastatin and Lovastatin but not Pitavastatin 
Dose-Dependently inhibited GSIS.  
 A general summary of the previous results is shown in Figures 15 and 16). Figure 
15 shows that simvastatin has the most severe inhibitory effect on GSIS followed by 
lovastatin. In contrast, pitavastatin appears to maintain GSIS as no significant difference 
was observed in GSIS values between control and pitavastatin-treated INS-1 cells. 
Simvastatin already significantly reduced the GSIS at the lowest dose 25 nM meanwhile 
lovastatin seemed to have a significant inhibitory effect on GSIS only after the dose was 
raised to 50 nM (Figure 15A).  
 In terms of the insulin content, both simvastatin and lovastatin appear to have 
similar effects to deplete insulin content at concentrations as low as 50 nM (Figure 15B). 
In contrast, insulin content from pitavastatin-exposed INS-1 cells began to diminish 
significantly only after exposure to the highest dose (200 nM). When we look at the effect 
of those three statins on GSIS after correcting for content, the GSIS as percent content 
mediated by simvastatin was relatively unchanged. This was opposed to the actions of 
lovastatin and pitavastatin where GSIS as percent insulin content tended to show an 
increase. These results may potentially demonstrate that reduction on GSIS mediated by 
simvastatin and lovastatin was associated to reduction in content. These findings imply that 
the mechanism of insulin exocytosis associated with glucose metabolism may not be 
affected.    
 
40  
Figure 15. Simvastatin and Lovastatin inhibited GSIS in a dose dependent manner 
(A) and Simvastatin and Lovastatin significantly reduced insulin content at 50 nM, 
100 nM & 200 nM while Pitavastatin significantly dropped content after 200 Nm (B). 
The graph above depicted effect of three distinct statins (simvastatin, lovastatin & pitavastatin) on 
GSIS and insulin content from INS-1 cells after chronic incubation of each statin for 3 days which 
were gathered from figure 9B, 10A, 11B, 12A, 13B & 14A. The results were conducted in 96-well 
plate and calculated as a mean ± S.E.M. *p<0.05, control vs 25 nM, 50 nM, 100 nM & 200 nM 
statins (one-way ANOVA followed by T-test). 
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Figure 16. Insulin secretion from figure 15B measured as percent content. The results 
indicate no inhibition of insulin release after it was normalized for its content. The graph 
above shows combination of three figures from fig. 10B, 12B & 14B. The results were conducted 
in 96-well plate and calculated as a mean ± S.E.M. *p<0.05, control vs 25 nM, 50 nM, 100 nM & 
200 nM statins (one-way ANOVA followed by T-test). 
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Time Course of Simvastatin, Lovastatin and Pitavastatin Effects on GSIS  
 The observed reduction in insulin content mediated by simvastatin and lovastatin 
at a low concentration of 50 nM as well as by pitavastatin at 200 nM, prompted us to 
examine the effect of the three statins on GSIS during acute incubation. We hypothesized 
that the decrease in insulin content was due to a hypersecretion of insulin in the early hours 
of statin exposure.  Therefore, we treated INS-1 cells with simvastatin, lovastatin and 
pitavastatin in 24-well plates for varying lengths of time (14, 24, 48 and 72 hours). 
 Figure 17 shows the individual GSIS values at each time measured (colored circles) 
as well as the linear trend for each group over time (solid colored lines). The zero time for 
each condition was normalized to the control and is marked by the single circle at time 0 
(purple). The control cells treated without statins had relatively stable values for GSIS over 
the time course of the experiment (black points and line). In concordance with GSIS 
response to chronic incubation, 24-, 48- and 72-hour exposure to simvastatin were all 
decreased compared to the zero simvastatin starting point. The level of secreted insulin was 
slightly increased after 14-hr incubation possibly indicating hypersecretion but the overall 
trend line indicated a dramatic decrease over time (red points and line). Lovastatin showed 
a decrease in GSIS over time similar to that of simvastatin, however unlike simvastatin this 
decrease was evident at the earliest time measured (31 % decreases at 14 hour), which 
resulted in a trend line with a decreased slope compared to simvastatin (red points and 
line). The GSIS response from pitavastatin-treated cells was not consistent resulting in a 
trendline that was offset from the control but with a similar flat slope (green points and 
line). Based on the trend lines in this single statin time course, we conclude that there was 
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neither reduction nor improvement in GSIS level with pitavastatin, which is similar to the 
control group. In contrast, the trend line in simvastatin and lovastatin indicated a continual 
reduction in insulin secretion even after 24 hrs. 
 
Figures 17. GSIS from INS-1 cells started to decrease at 12 & 24 hours by Lovastatin 
& Simvastatin, respectively. The dots represented the GSIS value at 0, 14, 24, 48 & 72 hours. 
The GSIS value from all statins at 0 hour is normalized to GSIS value from control group. The 
solid lines indicate the trendline of all dots of each statin from each time points. INS-1 cells were 
cultured in 11 mM glucose following the time course of acute incubation. On the day of experiment, 
the cells were acutely stimulated with 11 mM glucose RPMI without phenol red and serum.  
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Effect of Simvastatin and Pitavastatin on Intracellular Calcium Activity in INS-1 
Cells at low Glucose Stimulation 
The observed differences between simvastatin and pitavastatin to reduce insulin 
content and inhibit GSIS lead us to ask whether exposure to these statins caused differences 
in intracellular Ca2+ handling in response to the basal (1 mM) and physiological (4 mM) 
glucose concentrations. We used the Ca2+ dye fura-2 to determine activity or change in 
Ca2+ oscillations after three-days exposure to simvastatin and pitavastatin. Interestingly, 
our results show a robust oscillation of Ca2+ from simvastatin-treated INS-1 cells compared 
to Ca2+ oscillations in controlled cells and pitavastatin-treated INS-1 cells (Figure 20). 
Dramatic large amplitude oscillations started early at 1 mM glucose stimulation. 
Conversely, Ca2+ oscillations in pitavastatin-treated cells exhibit a comparable pattern to 
Ca2+ oscillations in no-statin-treated cells. 
In terms of the starting point of average Ca2+ level gained from these cells, there 
was no significant difference among all groups. The average Ca2+ was started from 0.73, 
0.82 and 0.81 in control group, simvastatin- and pitavastatin-treated INS-1 cells, 
respectively. Furthermore, there was no significant elevation in Ca2+ in all conditions 
(control, simvastatin and pitavastatin group) when the glucose concentration was raised 
from 1 mM to 4 mM. In the context of glucose dose response, this finding is consistent 
with previous studies in pancreatic ß-cells or islets by Henquin et al., (2006), Antunes et 
al., (2000), Heart et al., (2006) and Erion et al., (2014) that explained a discrepancy between 
Ca2+ and increase glucose stimulation. 
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Figure 18. Activity of intracellular Ca2+ in INS-1 Cells with simvastatin (200 nM) and 
pitavastatin (200 nM)) exposure. The cells were acutely stimulated in 1 mM glucose (basal) 
for 15 mins then glucose was raised to 4 mM (physiological) glucose for the next 20 to 25 minutes. 
The INS-1 cells were cultured in 11mM glucose for 4 days in total and statins were added for 3 
days. Error bars represent ± S.E.M. 
 
 
 
 
 
4 mM 1 mM 
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The Effect of Simvastatin on Kinetic Measurement of GSIS from INS-1 Cells  
High dynamic Ca2+ oscillations from simvastatin-exposed INS-1 cells lead us to 
measure the kinetics of insulin secretion, which require ß-cell perifusion to monitor 
oscillatory insulin secretion profiles. This measurement enables us to investigate the effects 
of chronic simvastatin treatment in GSIS oscillatory behavior, which is driven by glucose 
metabolism and Ca2+ influx.  
Despite the robust Ca2+ oscillations from simvastatin-treated ß-cells, the same 
behavior was not reflected in the kinetic GSIS measurement (Figure 21). It is interesting to 
find that both INS-1 from control and simvastatin group had almost identical insulin 
oscillatory pattern. The apparent difference is on the values of amplitude where 
simvastatin-treated INS-1 cells has much smaller amplitude compared to the control group. 
These results match with those in a previous study in pancreatic islets by Cunningham et 
al., (1996) which demonstrated insulin oscillations independent of Ca2+. They concluded 
that oscillations in Ca2+ are not required to drive oscillations in secretion. 
Although  Ca2+ is not the only key to insulin release in the pancreatic islet, it may 
play a permissive role (Deeney et al., 2001). Our findings could suggest that simvastatin 
could potentially lowers the cell sensitivity to Ca2+. Thus, in spite of the strong oscillatory 
behavior in Ca2+, INS-1 cells from simvastatin group has lower amplitude in insulin 
release. 
In the context of glucose dose response, at basal to physiological insulin stimulation 
(1 mM to 3 mM) both insulin oscillations in simvastatin and control group were mostly 
similar. At a closer look, insulin oscillations from the simvastatin group has more variable 
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irregular peaks compared to control which were exhibited after the glucose was raised from 
3 mM to 12 mM. 
 
Figure 19. Minimum inhibition of kinetic insulin secretion by simvastatin at 200 nM. 
The glucose concentration in the perifusion medium was changed from 1 mM to 3 mM then to 
maximum stimulation at 12 mM as indicated. The result is expressed as three data points averaged. 
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DISCUSSION 
 
 The increased incidence of T2D and its strong association with CVD have brought 
increased scrutiny to statins and raised concerns that statin use could promote development 
of type 2 diabetes (T2D) and mechanistic studies have been attempting to investigate the 
underlying mechanism between statins action and its effects on β-cell function. In this 
study, we demonstrate that inhibition of cholesterol biosynthesis mediated by different 
statins results in distinct effects on GSIS and insulin content during chronic and acute 
incubation. 
 Chronic exposure for 3 days by simvastatin and lovastatin in INS-1 cells cultured 
with excess glucose, dose dependently impaired the cells ability to release insulin. This 
was accompanied by a depletion in insulin content in a dose-dependent manner. 
Meanwhile, pitavastatin, another lipophilic statin, did not replicate the behavior of 
simvastatin and lovastatin. Rather, pitavastatin was found to preserve insulin content until 
the dose was raised to 200 nM. As a result, the GSIS from pitavastatin-treated INS-1 cells 
was maintained at the control level.  
 These findings lead us to suggest that reduction in glucose-stimulated insulin 
secretion was a consequence of diminishing content rather than an effect on the exocytotic 
mechanism. To test this conclusion, we showed that after normalizing the GSIS level for 
content, there was no reduction in insulin secretion. This would seem to indicate that 
insulin exocytosis was not affected by simvastatin, lovastatin and pitavastatin. 
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 Since all three statins are categorized as lipophilic statins, it was interesting to 
observe the contradictory effect between simvastatin and lovastatin versus pitavastatin. In 
the context of GSIS and insulin content, various reports have shown the adverse effect of 
lipophilic statins when compared to hydrophilic statins. Some studies have reported that 
the inhibition of insulin secretion in vitro parallels statin lipophilicity. Lipophilic statins 
diffuse more readily to the intracellular space and perturb cellular processes, which could 
lead to decreased insulin secretion in response to glucose (Yada et al., 1999). However, 
this study did not include pitavastatin, a lipophilic statin which is obtained synthetically. 
Therefore, our study is able to imply that the inhibitory effect of simvastatin and lovastatin 
on GSIS and insulin content is not necessarily correlated to this physico-chemical property. 
  As simvastatin and pitavastatin seemed to have the most adverse and the least 
harmful effect on GSIS, respectively, we then examined the impact of chronic exposure to 
both statins on intracellular Ca2+, which when increased stimulates insulin release. 
Simvastatin and pitavastatin did not reduce oscillations in intracellular Ca2+ when 
compared to control. Simvastatin, in fact increased the amplitude of oscillations in the INS-
1 cells. Our finding fits several studies that explain the correlation between decreased 
cholesterol and elevation of Ca2+. Hao & Bogan (2009) discovered that cholesterol 
depletion stimulates PIP2 hydrolysis. Reduced PIP2 increases the ATP sensitivity of the 
KATP channel, which results in increased membrane depolarization and promotes voltage-
gated Ca2+ influx. Furthermore, the elevation of Ca2+ is conducive to triggering PLC 
activity, which can further hydrolyze PIP2 in pancreatic islets allowing more closure of 
KATP channels (Tamarina et al., 2005). We suggest that Ca
2+ oscillations from simvastatin-
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exposed cells were more robust compared to control and pitavastatin-treated cells due to a 
greater lowering of plasma membrane cholesterol level.  
 Inversely, cholesterol-abundant cells may exhibit dampened intracellular Ca2+ 
oscillations. This is reflected in the control INS-1 cells that were cultured in high glucose 
which have increased intracellular lipid (Erion, 2015). We suggest that the small 
oscillations observed in the control condition are in part due to high plasma membrane 
cholesterol level. We also suggest that the elevated averaged Ca2+ from INS-1 cells treated 
with pitavastatin may be the result of more mild reduction in cholesterol level compared to 
simvastatin. This may increase the average intracellular Ca2+ without increasing the 
amplitude of oscillations.   
 Although depleted cholesterol in β-cells is known to increase triggering of GSIS 
through increasing Ca2+ influx, we did not see consistent results in our static GSIS 
experiments. The significant decrease in static GSIS by 25 nM to 200 nM simvastatin led 
us to measure the kinetics of insulin release. Surprisingly, the oscillations of insulin release 
from simvastatin-exposed INS-1 cells were not very different from the control. 
Furthermore, the increased amplitude Ca2+ oscillations from simvastatin-treated INS-1 
cells were not reflected in this kinetic measure of insulin release.  This could be due to a 
weakened Ca2+ affinity of synaptotagmin mediated by lower PIP2. Synaptotagmin is the 
major Ca2+ sensor on the membrane of secretory vesicles in β-cells which are involved in 
Ca2+-modulated insulin exocytosis (Lezzi et al., 2004). As described above, blocking 
cholesterol biosynthesis increases PIP2 hydrolysis which reduces plasma membrane PIP2 
and as a result stimulates Ca2+ influx. However, increased PIP2 can act to stimulate 
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exocytosis by increasing the affinity of Ca2+ to synaptotagmin, the Ca2+ sensor of 
exocytosis (Bogaart, 2012). Therefore, large amplitude Ca2+ oscillations from simvastatin-
treated INS-1 cells can be observed but fail to translate to larger oscillations in insulin 
release compared to control cells. 
 The experiments described above have all been performed after 72 hours chronic 
incubation with statins. Varying the time of exposure to statins we show that inhibition in 
GSIS occurred in as little as 12 hours. This reduction in insulin secretion was observed 
quicker with lovastatin at 14 hours, followed by simvastatin at 24 hours whereas 
pitavastatin exhibited an inconsistent decrease over time. Initially, we hypothesized that 
significant reduction in insulin content by simvastatin and lovastatin may be due to a 
hypersecretion during acute exposure. However, no consistent statin-induced increase in 
insulin release was measured after short incubation periods. 
 Previously, we predicted that reduction in GSIS by simvastatin and lovastatin could 
be solely due to the persistent decrease in insulin content. However, the effect of statins to 
potentially lower the plasma membrane cholesterol level and affect both Ca2+ influx and 
Ca2+ sensitivity suggests that the exocytotic machinery may also play an important role in 
altered insulin release.      
 In summary, pitavastatin seemed to have less inhibitory effects on GSIS and content 
compared to simvastatin and lovastatin. This would indicate that not all lipophilic statins 
have the same detrimental impact on GSIS and insulin content. In addition, the inhibition 
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of GSIS by simvastatin and lovastatin could be due not only to depletion of insulin content 
but also decreased Ca2+ sensitivity of insulin exocytosis. 
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